CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 197 enrolled
Drug / intervention
Iron Sucrose Solution for Injection +1 moredrug
Likely dose
Iron Sucrose Solution for Injection 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03658876
NCT03658876Phase 4Completed
CompareCT.gov

Predictors of Response to Iron and Erythropoietin Stimulating Agents

Imperial College London·interventional·Posted Sep 5, 2018·Updated Jul 5, 2019

In Brief

A Phase 4 clinical trial evaluating Iron Sucrose Solution for Injection and Epoetin Beta for Renal Failure Chronic and Anemia. Completed, enrolled 197 participants.

Detailed Summary

The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure Chronic, Anemia
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 5, 2018
Enrollment StartJun 3, 2015
Primary CompletionDec 31, 2016
Study CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.8 years ago

Interventions

Iron Sucrose Solution for Injectiondrug

200mg iron sucrose given on 5 successive haemodialysis sessions

Epoetin Betadrug

Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000